Plain-English translation of NCT06140966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment plan using combined with other medications for patients with newly diagnosed, aggressive multiple myeloma—a serious blood cancer. The study includes chemotherapy, a stem cell transplant, and ongoing medication to see if this combined approach can improve survival for patients whose disease is harder to treat. Researchers want to know if this medication and transplant strategy works better than current standard treatments for high-risk patients.
Patients with aggressive forms of multiple myeloma have much worse outcomes than those with standard disease and don't benefit as much from current treatments. This trial exists to test whether this new medication combination, combined with a stem cell transplant, can help these high-risk patients live longer.
You likely qualify if…
You likely don't qualify if…
Over several months, you would receive multiple rounds of induction chemotherapy with the study medication, followed by a stem cell transplant procedure. After recovery, you would receive consolidation chemotherapy, then transition to a maintenance phase lasting about a year where you take the medication in cycles. You would have frequent clinic visits, blood tests, and scans throughout to monitor how you're responding to treatment and manage any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China